ArticleMedicine2025
Pan-cancer analysis of PDGFRB: Laying the foundation for the development of targeted immunotherapy drugs.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Immunosuppressive roles of pericytes in cancer disease: insights from a systematic review and meta-analysis.Journal of translational medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
PDGFRB is a type III tyrosine-protein kinase that is abnormally expressed in various cancers and can serve as a biomarker for cancer prognosis, as studies have demonstrated. However, a pan-cancer analysis of PDGFRB has not yet been carried out. The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases were utilized to analyze PDGFRB expression levels. Differential expression of PDGFRB in standard, tumor, and different clinical stage samples was calculated using R software (version 3.6.4). Immunohistochemical staining for Cholangiocarcinoma (CHOL) and Esophageal carcinoma (ESCA) was conducted on clinical patient samples. High-quality prognostic datasets from TCGA have been published in previous studies. Additionally, the TARGET follow-up data were obtained as supplementary information, excluding models with a follow-up period of less than 30 days. After conducting a rain analysis of PDGFRB, Kaplan-Meier and univariate Cox regression analyses were performed using the R software package. The DNA tumor stemness scores, derived from methylation signatures for each tumor, were obtained from previous studies. Finally, the infiltration of immune cells was analyzed, and the Pearson correlation between PDGFRB and five immune pathway marker genes was assessed. PDGFRB exhibited differential expression across most tumor types in TCGA, indicating a correlation with poor survival outcomes. The expression of PDGFRB influences the regulation of the immune system and is closely associated with immune cell infiltration, immune checkpoints, immune-activating genes, immune suppressor genes, chemokines, and chemokine receptors. PDGFRB is a cancer gene closely associated with prognosis and immunity in cancer patients, and it may serve as an immune checkpoint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.